U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
TITUSVILLE, N.J., March 29, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.1,2 Co-developed as part of a collaboration with ViiV Healthcare, CABENUVA is the first and only complete long-acting HIV-1 treatment regimen, and the first to be made available for eligible adolescents, building on Janssen’s ongoing commitment to fighting HIV and improving HIV treatment options for young people living with HIV. CABENUVA is approved as a once-monthly or every-two-months treatment for HIV-1 in virologically suppressed adults and adolescents. It contains ViiV Healthcare’s cabotegravir extended-release injectable suspension in a single-dose vial and rilpivirine extended-release injectable suspension in a single-dose vial, a product of Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.“HIV remains one of the most significant challenges in global health, and as part of our decades-long commitment to fighting HIV, Janssen is working tirelessly to advance innovative ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: African Health | AIDS Vaccine | Allergy & Immunology | Australia Health | Back Pain | Biochemistry | Botswana Health | Brain | Breastfed | Canada Health | Cancer & Oncology | Carbamazepine | Cardiology | Cardiovascular | Centers for Disease Control and Prevention (CDC) | Chemistry | Child Development | Children | Chronic Pain | Clinical Trials | Depression | Dexamethasone | Drugs & Pharmacology | Epidemics | Epidemiology | Food and Drug Administration (FDA) | Genetics | Headache | Health Management | Heart | HIV AIDS | Hives | Hypertension | Infectious Diseases | Insomnia | Ireland Health | Learning | Legislation | Liver | Liver Disease | Men | Migraine | Miscarriage | National Institutes of Health (NIH) | Neurology | Neuroscience | Pain | Pediatrics | Pharmaceuticals | Phenobarbital | Phenytoin | Postnatal Depression | Pregnancy | Profits and Losses | Pulmonary Hypertension | Science | Skin | Sleep Disorders | Sleep Medicine | South Africa Health | Study | Suicide | Switzerland Health | Thailand Health | Uganda Health | Universities & Medical Training | Urology & Nephrology | USA Health | Vaccines | Virology